Press Release

X-Rx Announces Autotaxin Inhibitor Collaboration with Gilead Sciences

 

Wilmington, NC, November 11, 2015: X-Rx, Inc. announced today that it has entered into an exclusive agreement with Gilead Sciences, Inc. to develop X-Rx’s proprietary small molecule autotaxin (ATX) inhibitors.  ATX plays a key role in maintaining tissue homeostasis and is upregulated in many diseases, including idiopathic pulmonary fibrosis (IPF).  Inhibition of ATX leads to a reduction in lysophosphatidic acid production, which blocks signaling cascades that ultimately drive the development of fibrosis.

Under the terms of the agreement, X-Rx will receive an upfront payment and research funding to advance the lead molecule through early clinical development and to support the company in further developing its other pipeline assets.  X-Rx also may receive subsequent clinical milestone payments. X-Rx has granted Gilead the exclusive option to purchase the program.  Further financial terms were not disclosed.

“We are very pleased to partner with Gilead on the ATX drug development program as we seek to address the needs of patients with IPF,” says Lee E. Babiss, Ph.D. and CEO of X-Rx, Inc.  “This partnership underscores our capabilities and ability to successfully advance an efficient and high-quality drug discovery pipeline.”